Skip to main content

MRX-2843 + Osimertinib

MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

  • RegistryNCT04762199
  • PhasePhase 1
  • StatusRecruiting
  • ConditionAdvanced EGFR-Mutant Non-Small Cell Lung Cancer
  • SponsorEmory University
How MRX-2843 + Osimertinib worksNCT047621991 min

What the film says

Read the transcript

This trial is for adults with advanced non-small cell lung cancer with an EGFR mutation.

The idea: combine osimertinib, a standard pill for EGFR mutant lung cancer, with MRX-2843, a pill that blocks two enzymes, MerTK and FLT3. Blocking enzymes the cancer needs may stop tumor cells from growing.

The study looks for the best dose of MRX-2843 and its side effects.

This phase 1 study plans 69 patients. At Emory University's Winship Cancer Institute in Atlanta, Conor Steuer leads it.

Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT04762199

    Adults; advanced EGFR-mutant NSCLC; Osimertinib + MRX-2843 pills; Flt3/MerTK inhibitor; Blocking enzymes may stop growth; Best dose and side effects (+1 more lines)

The drug

What is being tested.

PRIMARY OBJECTIVES: I. Assess the safety and tolerability of MRX-2843 (MRX-2843) when administered along with osimertinib. II. Establish the recommended phase 2 dose (RP2D) of the tested combinations. SECONDARY OBJECTIVES: I. To observe and record anti-tumor activity. II. To perform biomarker profiling in order to identify potential predictive biomarker to optimize treatment efficacy. OUTLINE: This is a dose-escalation study of MRX-2843.

Patients receive osimertinib orally (PO) once daily (QD) and MRX-2843 PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for minimum of 30 days, or until resolution of treatment-related toxicity to =< grade 1, whichever is longer after removal from study.

The study

How the trial runs.

This phase Ib trial evaluates the best dose and side effects of MRX-2843 when given in combination with osimertinib in treating patients with EGFR gene mutant non-small cell lung cancer that has spread to other places in the body (advanced). MRX-2843 and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Patients must have histologically confirmed metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation including typical and atypical mutations in egfr exons 19 and 21
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • Patients in the expansion cohort must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm (>= 2 cm) by chest x-ray or as >= 10 mm (>= 1 cm) with computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam
  • Ability to safely swallow oral medication
  • Absolute neutrophil count >= 1500/mm^3
  • Platelet count >= 100,000/mm^3

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.